Lazard Asset Management
TMCI icon

Lazard Asset Management’s Treace Medical Concepts TMCI Stock Holding History

Lazard Asset Management’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,190
Closed -$30K – 2312
2025
Q2 		$30K Buy
+5,190
New +$33.8K ﹤0.01% 2086

Other funds holding TMCI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management's TMCI Position: Q3 2025 in Review

Lazard Asset Management sold out of Treace Medical Concepts (TMCI) in Q3 2025, closing a stake of 5,190 shares — an estimated $30K sold.

Lazard Asset Management first reported a position in TMCI in Q2 2025 and held it in 1 quarter. The position peaked at $30K in Q2 2025. 119 funds tracked by Wall St. Rank hold TMCI as of Q3 2025.

  • Lazard Asset Management reported no remaining Treace Medical Concepts position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 5,190 Treace Medical Concepts shares in Q3 2025, an estimated $30K.
  • Lazard Asset Management first reported a position in Treace Medical Concepts in Q2 2025 and held it in 1 quarter.
  • Lazard Asset Management's Treace Medical Concepts position peaked at $30K in Q2 2025.
  • 119 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.